Recent 8-K filings for CBLL

• August 10, 2026, 4:27 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q2 revenue up 33% to $28.1M; raises FY2026 guidance to $114-117M

  Total revenue $28.1M, up 33% YoY; product revenue $21.2M, subscription $6.9M.

• May 11, 2026, 4:16 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M

  Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.

• February 24, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Ceribell Q4 revenue $24.8M (+34% YoY); FY 2026 guidance $111-115M

  Full-year 2025 revenue $89.1M (+36% YoY); net loss $53.4M ($1.46/share).

• January 5, 2026, 6:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Ceribell receives FDA Breakthrough Device Designation for LVO stroke detection system

  FDA Breakthrough Device Designation granted for CeriBell's LVO stroke detection and monitoring solution.

• December 9, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Ceribell receives FDA 510(k) clearance for first delirium monitoring solution

  FDA cleared Ceribell's EEG-based delirium screening and monitoring system for critically ill patients.

• November 24, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Ceribell receives FDA 510(k) clearance for Clarity algorithm to detect seizures in neonates

  FDA clearance covers use of Clarity algorithm for electrographic seizure detection in newborns preterm and older through adults, the first AI-powered point-of-care EEG for all ages.

• November 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Ceribell Q3 revenue $22.6M (+31% YoY); raises FY 2025 guidance to $87-89M

  Product revenue $17.0M (+28%); subscription revenue $5.6M (+44%).

• August 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q2 revenue $21.2M (+38% YoY); raises FY2025 guidance to $85-88M

  Total revenue $21.2M, up 38% YoY from $15.3M; product revenue $15.9M, subscription $5.3M.

• June 20, 2025, 7:59 PM ET other material materiality 0.60 positive item 1.01item 9.01

  Ceribell exercises option to extend Stanford license exclusivity through patent expiration for $250K

  Exercised option on June 12, 2025 to extend exclusive license for brain wave detection devices.

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q1 revenue $20.5M (+42% YoY); raises FY2025 guidance to $83-87M

  Q1 total revenue $20.5M (+42% YoY); product $15.6M (+41%), subscription $4.9M (+45%).

• April 11, 2025, 7:59 PM ET other material materiality 0.75 negative item 7.01item 9.01

  CeriBell sees 8-10 ppt gross margin drag from 145% China tariffs after Q3 2025

  FY2024 gross margin 87%; tariffs on Chinese-sourced goods expected to reduce margin by 8-10 percentage points.

• February 25, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Ceribell Q4 revenue $18.5M (+41% YoY); FY2024 revenue $65.4M (+45%); guides FY2025 $81-85M

  Q4 revenue $18.5M (+41% YoY); product $14.1M, subscription $4.4M; gross margin 88%.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q3 revenue $17.2M (+48% YoY); net loss $10.4M; guides FY2024 rev $64.2-64.7M

  Product revenue $13.3M (+52%), subscription revenue $3.9M (+36%).

• October 15, 2024, 7:59 PM ET other material materiality 0.85 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  CeriBell closes IPO of 12.2M shares at $17.00, gross proceeds ~$207.3M

  IPO of 12,196,969 shares (including 1,590,909 overallotment shares) closed on Oct 15, 2024 at $17.00 per share.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

14 positive 1 negative 9 neutral

source · CBLL on sec.gov